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Summary
 
Calreticulin (CRT), a peptide-binding heat shock protein (HSP) of the endoplasmic reticulum
(ER), has been shown previously to associate with peptides transported into the ER by trans-
porter associated with antigen processing (Spee, P., and J. Neefjes. 1997. 
 
Eur. J. Immunol.
 
 27:
2441–2449). Our studies show that CRT preparations purified from tumors elicit specific im-
munity to the tumor used as the source of CRT but not to an antigenically distinct tumor. The
immunogenicity is attributed to the peptides associated with the CRT molecule and not to the
CRT molecule per se. It is further shown that CRT molecules can be complexed in vitro to
unglycosylated peptides and used to elicit peptide-specific CD8
 
1
 
 T cell response in spite of ex-
ogenous administration. These characteristics of CRT closely resemble those of HSPs gp96,
hsp90, and hsp70, although CRT has no apparent structural homologies to them.
Key words: heat shock protein • stress protein • antigen presentation • cytotoxic T 
lymphocyte response • cancer immunity
 
P
 
eptide-binding heat shock proteins (HSPs)
 
1
 
 of the cyto-
sol (hsp70, hsp90) and the endoplasmic reticulum (ER)
(gp96) have been shown to elicit antigen-specific cellular
immunity to tumor antigens (1–9), viral antigens (10), mi-
nor histocompatibility antigens (11), and model antigens
(12, 13) expressed by the cells from which the HSPs are
isolated. The basis of the general ability of HSP prepara-
tions to immunize specifically lies in the observation that
hsp70, hsp90, and gp96 are associated with a broad reper-
toire of peptides, including the antigenic peptides gener-
ated in any given cell or tissue (6, 10, 12). Immunogenic
HSP–peptide complexes can also be reconstituted in vitro
by complexing a given peptide with hsp70 or gp96 (13,
14). The mechanism through which HSP–peptide com-
plexes elicit peptide-specific immunity has been partially
elucidated: HSP–peptide complexes are taken up by pro-
fessional APCs and the peptides are processed and re-pre-
sented on the surface of the APC by the MHC I molecules
of the APC, which then stimulate antigen-specific CD8
 
1
 
 T
lymphocytes (15, 16).
The physiological function of the HSP–peptide com-
plexes within the cells of origin is unclear. It has been pro-
posed that HSPs constitute a relay-line of chaperones that
transport peptides from the point of their generation in the
cytosol to their being loaded onto the MHC I molecules in
the ER (17). Specifically, hsp90 and hsp70, the most abun-
dant cytosolic chaperones, have been proposed to transport
peptides to the heterodimeric transporters associated with
antigen processing (TAPs), whereas gp96, a major chaper-
one of the lumen of the ER, has been proposed to facilitate
assembly of the MHC I–
 
b
 
2 microglobulin–peptide com-
plexes in the ER. Recent studies by Spee and Neefjes (18)
have shown that TAP-transported peptides associate with
gp96, and indicate that another ER-resident chaperone,
calreticulin (CRT), is a recipient of the TAP-transported
glycosylated peptides. The studies reported here were un-
dertaken to test whether CRT would, by virtue of its pep-
tide-binding ability and because it is an HSP, elicit tumor
immunity if purified from tumor cells, and peptide-specific
immunity if complexed with antigenic peptides in vitro.
 
Materials and Methods
 
Mice and Antibodies.
 
BALB/cJ and C57BL/6 mice were ob-
tained from The Jackson Laboratory. Antibodies to CRT and pro-
tein disulfide isomerase (PDI) were purchased from Affinity
BioReagents, and antibodies to gp96 were obtained from NeoMar-
kers. A rabbit serum to a synthetic peptide derived from the se-
quence of human Erp57 was a gift from Peter Cresswell (Yale
University, New Haven, CT).
 
1
 
Abbreviations used in this paper:
 
 CRT, calreticulin; ER, endoplasmic reticu-
lum; HSP, heat shock protein; PDI, protein disulfide isomerase; TAP, trans-
porter associated with antigen processing; VSV, vesicular stomatitis virus. 
798
 
Calreticulin–Peptide Complexes Elicit Peptide-specific Immunity
 
Tumor Cell Lines.
 
Methylcholanthrene-induced fibrosarcomas
Meth A and CMS5 (BALB/c) have been described previously
(2). Meth A was maintained in ascites formed in BALB/cJ mice
by weekly intraperitoneal passage of cells.
 
Purification of gp96 and CRT.
 
A 40-ml Meth A cell pellet (or
equivalent wet weight of mouse liver) was homogenized in 160 ml
of hypotonic buffer (30 mM NaHCO
 
3
 
, 1 mM PMSF, pH 7.1)
and a 100,000 
 
g
 
 supernatant was obtained. Solid ammonium sul-
fate was added to bring the solution to 50% saturation. This was
centrifuged at 14,000 rpm for 30 min. The precipitate was dis-
carded and the supernatant was subjected to subsequent fraction-
ation at 80% ammonium sulphate. After centrifugation at 14,000
rpm for 30 min the precipitate was solubilized in PBS contain-
ing 2 mM Ca
 
2
 
1
 
 and 2 mM Mg
 
2
 
1
 
. This was applied to a Con
A–Sepharose column (Pharmacia). The Con A–bound proteins were
used for purification of gp96 as previously described (2). The buffer
of Con A unbound material was changed to 25 mM Na citrate
buffer, pH 5.3, by PD-10 column (Sephadex G-25; Pharmacia
Biotech.). It was then applied to the CM-Sephadex C-50 column.
The buffer of unbound of CM-Sephadex was then changed to 19
mM Na-phosphate buffer, pH 6.1 by PD-10 columns. It was then
applied to the DEAE-sephacel column and eluted with a linear
gradient of 0.15–0.5 M NaCl in 20 mM Na-phosphate buffer. The
CRT-containing fractions were identified by immunoblots.
 
Tumor Rejection Assay.
 
6-wk-old female BALB/cJ mice were
immunized subcutaneously with gp96 or CRT or PBS in a 200 
 
m
 
l
vol twice at weekly intervals. Mice were challenged intradermally
1 wk after last immunization with 100,000 live tumor cells. Tu-
mor diameter was measured every 2–3 d.
 
Complexing In Vitro of Peptide to gp96 or CRT.
 
Gp96 or CRT
was mixed with vesicular stomatitis virus (VSV)19 peptide in a
50:1 peptide/protein molar ratio in 0.7 M NaCl in Na-phosphate
buffer (for gp96) or 20 mM Na-phosphate buffer (for CRT) and
heated at 50
 
8
 
C for 10 min, then incubated at room temperature
for 30 min. Excess free peptide was removed with PBS using mi-
crocon 10 (Amicon, Inc.).
 
Induction of Cytotoxic T Cells.
 
C57BL/6 mice were immunized
intraperitoneally with 50 
 
m
 
g of gp96 or 27.5 
 
m
 
g of CRT com-
plexed with VSV19 peptide. 10 d later, recipient spleens were re-
moved and splenocytes were stimulated with VSV8 synthetic pep-
tide at 1 
 
m
 
M concentration. After 5 d, mixed lymphocyte tumor
cultures were tested for cytotoxicity in a Cr-release assay using EL4
cells alone and EL4 cells pulsed with VSV8 peptide as targets.
 
Results
 
Tumor-specific Immunogenicity of Tumor-derived gp96 and
CRT Preparations.
 
Apparently homogenous preparations
of gp96 and CRT were obtained from Meth A cells. The
two proteins were recognized by the respective antibodies
on immunoblots (Fig. 1). As CRT has a mol wt very simi-
lar to two other chaperones, PDI (18) and Erp57 (28),
CRT preparations were immunoblotted with antibodies to
each, as described in Materials and Methods. Although the
antibodies recognized the cognate proteins in control blots,
neither antibody detected a corresponding protein in puri-
fied CRT preparations (Fig. 2). BALB/cJ mice were im-
munized twice at weekly intervals with a 20-
 
m
 
g dose of
purified gp96 or an equimolar dose (11 
 
m
 
g and a lower
dose of 5.5 
 
m
 
g) of CRT and were challenged with 100,000
live Meth A cells 1 wk after the second immunization. Tu-
mors grew progressively in all buffer-immunized mice, but
mice immunized with the Meth A–gp96 or Meth A–CRT
preparation were equally protected from tumor growth.
The immunogenicity of CRT was dose dependent, as mice
immunized with half the effective dose succumbed to tu-
mor challenge. Furthermore, mice immunized with Meth
A–CRT were found to be not resistant to challenge with
the antigenically distinct BALB/cJ fibrosarcoma CMS5, in-
dicating the tumor-specificity of immunogenicity of Meth
A–CRT. In a further demonstration of specificity, immu-
nization with homogenous preparations of gp96 or CRT
from BALB/cJ mouse liver did not elicit immunity to chal-
lenge with Meth A sarcoma at any dose tested (Fig. 3).
Because Con A chromatography was used in purification
of both gp96 and CRT and because Con A is known to
stimulate monocytes and T lymphocytes, the possibility
that the immunogenicity of CRT and gp96 preparations
observed here derives from a Con A contamination of our
preparations should be considered. Three observations rule
out this possibility: the specificity of immunogenicity of tu-
mor-derived HSP preparations, as has been demonstrated
repeatedly in several studies from our laboratory (1, 2) and
by other groups (11) argues against such a nonspecific ef-
fect. Furthermore, in a routine, periodic screening of gp96
preparations with anti–Con A antibodies over the years,
such contamination has not been observed, nor has inclu-
sion of 
 
a
 
-methyl pyranoside in the immunizing prepara-
tions reduced the immunogenicity of HSP preparations
(data not shown).
Figure 1. Gp96 and CRT
preparations. Gp96 and CRT
purified from Meth A sarcoma
and liver of BALB/cJ mice were
resolved by SDS-PAGE, silver-
stained, or immunoblotted using
antibodies as described in Mate-
rials and Methods.
Figure 2. CRT preparation is
free of other peptide-binding pro-
teins of similar size. CRT prepara-
tions from Meth A sarcoma were
resolved on SDS-PAGE and were
immunoblotted with antibodies to
Erp 57 or PDI (as described in
Materials and Methods). The lane
marked 2 was silver-stained directly and was not immunoblotted. Meth A
cell lysate was used as source of protein for each immunoblot. 
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Association of CRT Molecules with Peptides In Vivo and In
Vitro.
 
The immunogenicity of tumor-derived but not
normal tissue–derived CRT is reminiscent of similar obser-
vations with the HSPs gp96, hsp90, and hsp70. In those in-
stances, the immunogenicity was demonstrated to derive
from HSP-associated peptides and not the HSPs per se.
The possibility that CRT molecules are associated with
peptides was considered. Because CRT is an ATP-binding
protein (19, 20), and as hsp70–ATP interaction has been
shown to result in dissociation of peptides from hsp70 (6),
the ability of ATP to dissociate peptides from CRT was
tested. It was observed that treatment of homogeneous
preparations of CRT with ATP did not dissociate peptides
from CRT under conditions that led to dissociation of
peptides from hsp70 (Fig. 4). Interestingly, treatment of
gp96 with ATP also did not result in elution of associated
peptides, although gp96 is an ATP-binding protein (21).
These observations must be considered with the caveat that
ATP binding by CRT might require conditions other than
those used for hsp70, hsp90, or gp96. Although this possi-
bility is considered unlikely because of the conserved ATP-
binding domains present in ATP-binding proteins (22), our
observations do not rule it out.
The possibility that the peptides bound to CRT in vivo
can be exchanged with exogenous peptides at high temper-
atures was tested. The procedure shown to be effective
with other HSPs (13) was tested. CRT preparations, and
gp96 preparations as a positive control, were incubated
with radio-iodinated peptide VSV19 (NH
 
2
 
-Ser-Leu-Ser-
Asp-Leu-Arg-Gly-Tyr-Val-Tyr-Gln-Gly-Leu-Lys-Ser-Asn-
Val-Ser-COOH which is extended on the NH
 
2
 
 and
COOH termini of K
 
b
 
-binding VSV nucleocapsid protein
epitope VSV8, underlined) at 25
 
8
 
C, 37
 
8
 
C, or 50
 
8
 
C, fol-
lowed by 30 min at room temperature. Equimolar quanti-
ties of each protein were used so that the molar ratio of
peptide to protein was the same in each lane. The samples
were analyzed by SDS-PAGE followed by Coomassie
staining (to determine protein content) and by autoradiog-
raphy (to determine the bound peptide) (Fig. 5). It was ob-
served that CRT associated with exogenous radiolabeled
peptides in a temperature-dependent manner and that
CRT–peptide complexes remained stable under conditions
of SDS-PAGE. Quantitative analysis of bound peptides
indicated that under the conditions used for peptide-
exchange in vitro, 
 
z
 
2% of the CRT molecules received
exogenous peptides at 50
 
8
 
C, and at a lower temperature
such as 37
 
8
 
C only half as many CRT molecules could asso-
ciate with the exogenous peptide. When gp96 and CRT
were used together, such that they had to compete for the
same pool of peptides under the same conditions, gp96 was
observed to bind peptides two to three times more effi-
ciently than CRT.
Figure 3. Immunogenicity of CRT and gp96 preparations from Meth
A sarcoma. Mice were immunized with 20 mg of gp96 or 5.5 and 11 mg
of CRT (molar equivalent of 10 and 20 mg of gp96) preparations from
Meth A sarcoma or normal liver of BALB/cJ mice as indicated. Immuni-
zation was carried out in 200 ml vol subcutaneously twice at a weekly in-
terval. Mice were challenged with 100,000 live Meth A cells intrader-
mally 1 wk after the last immunization. Each line represents the kinetics
of tumor growth in one mouse.
Figure 4. Interaction of CRT, gp96, and hsp70 with ATP or ADP.
CRT, gp96, or hsp70 were purified from Meth A cells and were incu-
bated with Tris-buffer containing 150 mM NaCl and 1 mM dithiothreitol
at pH 8.0 or the above buffer containing 10 mM ATP or ADP and 2 mM
Mg21 and 0.5 mM Ca21 at room temperature for 2 h. The mixtures were
centrifuged through centricon 10 and the eluates were applied to a re-
verse phase column R2H. The x-axis represents elution time and the
y-axis represents the absorbance at 214 nm. Specific peaks were obtained
from hsp70 treated with ATP but not with ADP or with buffer alone.
Peptides could not be eluted from gp96 or CRT after treatment with
ATP or ADP. A, buffer; B, plus ATP; C, plus ADP. 
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Generation of VSV-specific CTLs in Mice Immunized with
CRT–peptide Complexes Reconstituted In Vitro.
 
The ability
of CRT to act as a CD8
 
1
 
 response-eliciting adjuvant was
tested. The VSV19 peptide was complexed in vitro with
either gp96 or CRT at 50
 
8
 
C for 10 min, followed by incu-
bation at room temperature for 30 min. C57BL/6 mice
were immunized with the reconstituted complexes (50 
 
m
 
g
of gp96 or 27.5 
 
m
 
g of CRT complexed with VSV19), or
VSV19 alone, or gp96 or CRT alone without complexing.
Spleen cells of immunized mice were cultured with the
VSV8 and tested for cytotoxic activity on 
 
51
 
Cr-labeled EL4
cells or EL4 pulsed with the VSV8 peptide as targets. It was
observed that spleen cells of mice immunized with CRT–
peptide complexes showed peptide-specific CTL activity,
whereas splenocytes of mice immunized with peptide or
CRT alone showed no cytotoxic activity (Fig. 6). Similar
results were obtained with gp96–peptide complexes. Based
on the quantity of peptides bound to CRT, these results
suggest that 
 
z
 
20 ng of VSV19 or 5.7 
 
3 
 
10
 
12
 
 molecules of
VSV19 coupled to CRT are sufficient to elicit a CD8
 
1
 
CTL response. The in vitro complexing studies were car-
ried out with two variations: those where the CRT used
for complexing with peptides was derived from syngeneic
C57BL/6 mice and those where it was derived from allo-
geneic BALB/cJ mice. It was observed that CRT of either
haplotype could be complexed to VSV19 and could be
used to immunize C57BL/6 mice to elicit an H-2
 
b
 
–
restricted CTL response against VSV8 (Fig. 6).
 
Discussion
 
CRT is a calcium-binding protein of the ER and has
been shown to be involved in the folding and assembly of
MHC I molecules. Recent observations by Spee and
Neefjes (18) demonstrate that peptides transported into the
lumen of the ER by the TAP molecule associate with gp96
as well as with PDI and CRT. That study showed the gen-
eral ability of CRT to bind to proteins as well as to gly-
cosylated peptides of specific sequences inside lumen of the
ER. Association of CRT with peptides as well as the evi-
dence of CRT to be associated with MHC I molecule dur-
ing its folding and assembly (23–25) makes CRT a poten-
tial candidate of the relay line of HSPs during antigen
processing and presentation by MHC I molecules, as we
had suggested previously (17).
In our studies, CRT and gp96 bind peptide with com-
parable efficiency in vitro, when each is tested alone. In a
competition assay, gp96 binds to the longer peptide more
efficiently than CRT, but when gp96 is not present in the
assay, CRT binds to the peptide as efficiently as gp96. Al-
though Spee and Neefjes (18) demonstrated that only gly-
cosylated peptides are accepted by CRT in their assay, the
peptide complexed in vitro in the present study is ungly-
cosylated. This suggests either that the requirement for gly-
cosylation of peptides for their acceptance by CRT in the
lumen of the ER is not absolute, or that such apparent re-
quirement is a peculiarity of the assay used in the study of
Spee and Neefjes (18). The possibility should also be enter-
tained that although CRT has the capacity to bind both
glycosylated and unglycosylated peptides, only glycosylated
peptides are routed to it in vivo, due to the intricacies of
the peptide trafficking from the cytosol to the ER. The fact
that calnexin, a protein related to CRT, is a chaperone for
a wide array of glycosylated integral membrane protein,
and has been defined as a lectin (26), is consistent with this
possibility. This line of reasoning also raises the question of
whether calnexin, as an integral membrane protein or in a
soluble luminal form, has the capacity for binding peptides
in vivo and the capacity to immunize.
The mechanism by which CRT–peptide complex elicits
immunity is presently unknown. It is conceivable that it is
Figure 5. CRT binds to pep-
tides in vitro. CRT or gp96 (40
pmol) were incubated with iodi-
nated synthetic peptide (2 nmol,
NH2-Ser-Leu-Ser-Asp-Leu-Arg-
Gly-Tyr-Val-Tyr-Gln-Gly-Leu-
Lys-Ser-Asn-Val-Ser-COOH) in
phosphate buffer in 20 ml reac-
tion volume at 258C for 20 min,
378C for 1 h, or 508C for 10 min. After a brief centrifugation, the
mixtures were incubated at 258C for another 30 min. Samples were ana-
lyzed by SDS-PAGE and staining followed by autoradiography of the
stained gel.
Figure 6. CRT-peptide complex reconstituted in vitro primes mice
for antigen-specific CTL response. Mice were immunized with gp96
alone (50 mg), CRT alone (27.5 mg), peptide alone (50 mg), gp96–pep-
tide complex (50 mg), or CRT–peptide complex (27.5 mg). After 10 d,
spleens were removed and stimulated with VSV8 peptide (1 mM). The
lymphocyte cultures were tested for cytotoxic activity on 51Cr-labeled
EL4 cells or EL4 cells pulsed with the VSV8 peptide as targets. Open
symbols, EL4; filled symbols, EL4 plus VSV8. 
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similar to the mechanism by which gp96–peptide com-
plexes elicit immunity, which includes a receptor through
which gp96 is taken up by the professional APCs and the
peptides are re-presented. A crucial question in this regard
is whether this is a common receptor for the HSPs or
whether the mechanisms are different. This is particularly
intriguing since gp96, hsp70, or CRT molecules have no
structural homologies.
Binding of peptides by CRT provides evidence of the
generality of the peptide-binding property of HSPs and
of the immunogenicity of such HSP–peptide complexes.
From an evolutionary perspective, considering the broad
chaperoning function of HSPs and the association of HSPs
with the degradative machinery of cells, this is not surpris-
ing. However, it is interesting to note that the hsp70,
hsp90, gp96 and CRT molecules do not share any obvious
sequences or other structural homology. The possibility
that their peptide binding pockets may share conforma-
tional similarities despite the lack of structural homology,
clearly exists and will be instructive with regard to evolu-
tion of peptide-binding proteins including the MHC mol-
ecules (27). Our previous observation that complexes of
non-HSPs, such as serum albumin with peptides, do not
elicit peptide-specific CTLs (13) suggest that the immuno-
genicity does not result solely and inevitably from peptide
binding and that the immunogenicity of HSP–peptide
complexes is unique, deriving perhaps from specific inter-
action between HSPs and APCs (16).
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Note added in proof.
 
 During the course of these studies, we have learned that C. Nicchita, E. Gilboa, and col-
leagues have independently discovered that calreticulin can elicit, in a cell- and tumor-specific manner, CTL
responses (Nair, S., P. Wearsch, D.A. Mitchell, J.J. Wassenberg, E. Gilboa, and C.V. Nicchita. Calreticulin
displays in vivo peptide binding activity and can elicit cytotoxic T lymphocyte responses against bound pep-
tides. 
 
J. Immunol.
 
 In press.).
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